Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The lawsuit contends that ADMA Biologics failed to disclose critical information during the specified period, specifically regarding undisclosed related party transactions and the use of channel stuffing to artificially inflate revenue figures. Plaintiffs argue that these practices rendered the company’s public statements about its business operations and financial health materially false or misleading.

Investors who purchased shares during the class period are not currently represented by counsel unless they choose to retain one. While the role of lead plaintiff involves directing the litigation on behalf of the class, shareholders may also choose to remain absent class members. Participation in any eventual recovery does not require serving as a lead plaintiff. The Rosen Law Firm, which is soliciting participants for the action, emphasizes that no class has been certified at this stage of the proceedings.